PD-1/L1抑制剂在胃癌治疗中的研究进展

Research progress of PD-1/L1 inhibitors in the treatment of gastric cancer

免疫治疗是近年来的热门研究领域。PD-1/L1抑制剂通过阻断PD-1与PD-L1的结合,阻断负向调控信号,使T细胞恢复活性,从而增强免疫应答。PD-1/L1抑制剂包括纳武利尤单抗、帕博利珠单抗、替雷利珠单抗、卡瑞利珠单抗、信迪利单抗等。研究表明,PD-1/L1抑制剂单药或联合其他治疗方案能够提高胃癌患者总生存率。

Immunotherapy is a popular research field in recent years.PD-1/L1 inhibitors enhance the immune response by blocking the binding of PD-1 and PD-L1,blocking the negative regulatory signal,and restoring the activity of T cells.PD-1/L1 inhibitors include navullizumab,polizumab,tirelizumab,carilizumab,cindilizumab,etc.Studies have shown that PD-1/L1 inhibitor monotherapy or combined with other treatment regimens can improve overall survival in patients with gastric cancer.